VanEck Video Gaming and eSports ETF vs Summit Therapeutics Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.92 (market cap $248.06M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 55.3× VanEck Video Gaming and eSports ETF's market cap, and VanEck Video Gaming and eSports ETF is more actively traded (13,622 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Summit Therapeutics Inc for 16 Days on average.
| ESPO | SMMT | |
|---|---|---|
Market Cap | $248.06M | $13.71B |
Volume | 13,622 | 6,173,057 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $26.38 |
52-Week Low | $85.25 | $12.43 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | — | $13.04B |
Signals from Pluang's Aura AI — not financial advice
ESPO stock shows strong technical momentum, gaining 2.87% to $100.11 with a bullish moving average signal. The stock trades near resistance levels at $98-$99 while maintaining support at $97. Technical indicators show mixed signals with neutral RSI readings but positive ADX momentum. Fundamental data remains limited pending updated financial disclosures.
The technical setup suggests near-term upside potential if resistance levels are breached, though limited fundamental visibility warrants caution. Key risks include lack of recent financial data and market volatility. Investors require updated earnings reports and analyst coverage for proper valuation assessment before establishing positions.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →